Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics
TVTX Price/Volume Stats
| Current price | $5.99 | 52-week high | $22.75 |
| Prev. close | $6.15 | 52-week low | $5.25 |
| Day low | $5.94 | Volume | 1,313,900 |
| Day high | $6.34 | Avg. volume | 1,249,554 |
| 50-day MA | $7.70 | Dividend yield | N/A |
| 200-day MA | $9.75 | Market Cap | 455.89M |
TVTX Stock Price Chart Interactive Chart >
Travere Therapeutics, Inc. (TVTX) Company Bio
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.
Latest TVTX News From Around the Web
Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare genetic |
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGSAfter meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval Following engagement with the FDA on the two-year results from the Phase 3 DUPLEX Study in FSGS, Company conducting additional analyses of FSGS data and plans to re-engage FDA in 2024 Company is implementing a strategic reorganization to further focus near-term resources on ongoing FI |
Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years agoAs every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses... |
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceSAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for li |
Travere Therapeutics Reports Third Quarter 2023 Financial ResultsReceived 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled $8 million for the third quarter of 2023 Phase 3 PROTECT and DUPLEX Studies of sparsentan presented as ASN Kidney Week Late Breakers and simultaneously published in The Lancet and NEJM, respectively Completed sale of bile acid product portfolio for up to $445 million including potential future milestone-based payments, adv |
TVTX Price Returns
| 1-mo | -19.92% |
| 3-mo | -31.46% |
| 6-mo | -17.15% |
| 1-year | -72.46% |
| 3-year | -75.87% |
| 5-year | N/A |
| YTD | -33.37% |
| 2023 | -57.25% |
| 2022 | -32.25% |
| 2021 | 13.89% |
| 2020 | 91.94% |
| 2019 | N/A |
Loading social stream, please wait...